BND-35
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model[1].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Peretz T, et al. BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment[J]. Cancer Research, 2024, 84 (6_Supplement) : 3920-3920.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS9020210-01 0.02 mg (E-Coli)
Recombinant Human Lupus La protein (SSB)
Sign In for Pricing
View Details MBS9020210-02 0.1 mg (E-Coli)
Recombinant Human Lupus La protein (SSB)
Sign In for Pricing
View Details MBS9020210-03 1 mg (E-Coli)
Recombinant Human Lupus La protein (SSB)
Sign In for Pricing
View Details MBS9020210-04 5x 1 mg (E-Coli)
Recombinant Human Lupus La protein (SSB)
Sign In for Pricing
View Details 